BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1844 related articles for article (PubMed ID: 17252575)

  • 61. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer.
    Zimmer LA; McCook B; Meltzer C; Fukui M; Bascom D; Snyderman C; Townsend DW; Johnson JT
    Otolaryngol Head Neck Surg; 2003 Feb; 128(2):178-84. PubMed ID: 12601311
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
    Jiménez-Bonilla JF; Quirce R; Martínez-Rodríguez I; Banzo I; Rubio-Vassallo AS; Del Castillo-Matos R; Ortega-Nava F; Martínez-Amador N; Ibáñez-Bravo S; Carril JM
    Lung Cancer; 2013 Jul; 81(1):71-6. PubMed ID: 23597930
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
    Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
    [TBL] [Abstract][Full Text] [Related]  

  • 64. How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?
    Wang G; Lau EW; Shakher R; Rischin D; Ware RE; Hong E; Binns DS; Hogg A; Drummond E; Hicks RJ
    Cancer; 2007 Jan; 109(1):117-24. PubMed ID: 17133406
    [TBL] [Abstract][Full Text] [Related]  

  • 65. FDG PET for the study of primary hepatic malignancies in children.
    Mody RJ; Pohlen JA; Malde S; Strouse PJ; Shulkin BL
    Pediatr Blood Cancer; 2006 Jul; 47(1):51-5. PubMed ID: 16078228
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Importance of adrenal incidentaloma in patients with a history of malignancy.
    Frilling A; Tecklenborg K; Weber F; Kühl H; Müller S; Stamatis G; Broelsch C
    Surgery; 2004 Dec; 136(6):1289-96. PubMed ID: 15657589
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.
    Schoellnast H; Larson SM; Nehmeh SA; Carrasquillo JA; Thornton RH; Solomon SB
    Cardiovasc Intervent Radiol; 2011 Feb; 34 Suppl 2():S182-5. PubMed ID: 20508937
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
    Chen Z; Li X; Li F; Ouyang Q; Yu T
    Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Can (18)F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?
    Kang S; Ahn BC; Hong CM; Song BI; Lee HJ; Jeong SY; Lee SW; Lee J; Lee SJ
    Nuklearmedizin; 2011; 50(3):116-21. PubMed ID: 21246162
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
    J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Utility of positron emission tomography in sarcomas.
    Schuetze SM
    Curr Opin Oncol; 2006 Jul; 18(4):369-73. PubMed ID: 16721133
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas.
    Kao YH; Saad U; Tan AE; Magsombol BM; Padhy AK
    Acta Radiol; 2011 May; 52(4):463-6. PubMed ID: 21498277
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Detection of unknown primary tumor in a patient with cerebellar metastasis using FDG PET-CT: case report].
    Ishiguro T; Fu Y; Sadatou T; Shimokawa N; Shibamoto K
    No Shinkei Geka; 2006 Oct; 34(10):1027-32. PubMed ID: 17052015
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Endometriosis with FDG uptake on PET.
    Jeffry L; Kerrou K; Camatte S; Metzger U; Lelièvre L; Talbot JN; Lecuru F
    Eur J Obstet Gynecol Reprod Biol; 2004 Dec; 117(2):236-9. PubMed ID: 15541863
    [TBL] [Abstract][Full Text] [Related]  

  • 77. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M; Eigtved AI; Specht L
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
    Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
    J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score.
    Engenhart R; Kimmig BN; Strauss LG; Höver KH; Romahn J; Haberkorn U; van Kaick G; Wannenmacher M
    Strahlenther Onkol; 1992 Apr; 168(4):203-12. PubMed ID: 1574769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 93.